Search

Viking Therapeutics Inc

Închisă

SectorSănătate

29.92 -4.65

Rezumat

Modificarea prețului

24h

Curent

Minim

29.67

Maxim

31.52

Indicatori cheie

By Trading Economics

Venit

30M

-128M

EPS

-1.1

Angajați

65

EBITDA

30M

-128M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+185.71% upside

Dividende

By Acuity

Următoarele câștiguri

21 oct. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-371M

3.7B

Deschiderea anterioară

34.57

Închiderea anterioară

29.92

Sentimentul știrilor

By Acuity

50%

50%

129 / 339 Clasament în Healthcare

Viking Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

15 sept. 2026, 23:02 UTC

Viking Therapeutics Inc shares are higher during after-market hours, reflecting broader market trends despite recent economic indicators suggesting a slowdown in manufacturing.

14 sept. 2026, 19:36 UTC

Viking Therapeutics Inc shares are lower, continuing a trend of declines amid broader market weakness and rising crude oil prices affecting sentiment.

11 sept. 2026, 23:06 UTC

Viking Therapeutics Inc. shares are higher in after-market trading, despite routine fluctuations, and remain below their 20-day moving average.

10 sept. 2026, 20:07 UTC

Correlated Moves
Social Media

Viking Therapeutics Inc shares are lower, influenced by a declining broader market and volatility in the biotech sector amid rising Treasury yields and inflation concerns.

9 sept. 2026, 23:11 UTC

Viking Therapeutics Inc shares are higher in after-market trading, recovering from earlier lows despite being below the 20-day moving average. No specific news was identified.

2 sept. 2026, 19:46 UTC

Viking Therapeutics Inc shares are lower today, pulling back from earlier session highs amid broader market concerns over rising U.S. Treasury yields.

31 aug. 2026, 19:36 UTC

Viking Therapeutics shares are higher today, despite earlier pressure, amid broader market dynamics influenced by rising interest rate expectations following comments from the Fed.

29 aug. 2026, 00:01 UTC

Viking Therapeutics Inc shares rose in after-market trading, reflecting a notable increase since Friday's close, despite no specific news driving the movement.

28 aug. 2026, 23:36 UTC

Viking Therapeutics Inc. shares are higher in after-market trading, gaining since Friday's close, despite fluctuations and remaining below the 20-day moving average.

27 aug. 2026, 23:02 UTC

Viking Therapeutics Inc shares are higher in after-market hours following notable volatility during the session, despite no specific news to explain the movement.

26 aug. 2026, 19:16 UTC

Viking Therapeutics Inc shares are higher today, though no specific news was identified to explain the price movement. The stock remains above its 20-day moving average.

25 aug. 2026, 23:16 UTC

Viking Therapeutics shares are lower in after-market hours amid broader market volatility, with falling oil prices and geopolitical developments affecting investor sentiment.

24 aug. 2026, 19:56 UTC

Social Media

Viking Therapeutics Inc shares are lower today, continuing a decline since Friday. Social media discussions highlight anticipation for upcoming data before Labor Day.

20 aug. 2026, 20:06 UTC

Macro Event
Social Media

Viking Therapeutics Inc shares are lower, impacted by labor market data and heightened volatility, despite social media discussions suggesting potential recovery from a clinical trial.

19 aug. 2026, 23:16 UTC

Viking Therapeutics Inc shares are higher in after-market hours, reflecting a gain since Wednesday's close and remaining above the 20-day moving average.

18 aug. 2026, 19:16 UTC

Viking Therapeutics Inc shares are lower today, with no specific news driving the decline amid rising U.S. Treasury yields affecting the biotechnology sector.

17 aug. 2026, 23:06 UTC

Viking Therapeutics Inc shares are higher in after-market trading, reflecting unusual strength. No specific company news was identified to explain the price movement.

14 aug. 2026, 23:06 UTC

Viking Therapeutics Inc shares are lower in after-market hours, trading at the lower end of their one-month range and below the 20-day moving average.

13 aug. 2026, 23:16 UTC

Viking Therapeutics Inc shares are lower in after-market trading, with no specific news identified to explain the decline. The stock is near its one-month low.

12 aug. 2026, 23:26 UTC

Viking Therapeutics Inc is trading lower in after-market hours, reflecting notable weakness with no specific news identified to explain the decline.

7 aug. 2026, 19:36 UTC

Social Media

Viking Therapeutics is rising amid broader market gains and anticipation of VK2809 trial results, with analysts noting potential for improved market position.

6 aug. 2026, 23:16 UTC

Social Media

Viking Therapeutics Inc gains in after-market hours amid discussions on pharmacokinetic modeling and anticipated VKTX maintenance readout results.

5 aug. 2026, 22:51 UTC

Viking Therapeutics Inc. shares are lower in after-market hours, continuing a decline from Wednesday's close amid unusual volatility and trading below the 20-day moving average.

4 aug. 2026, 23:02 UTC

Social Media

Viking Therapeutics Inc shares are lower in after-market hours amid routine trading. The stock remains below its 20-day moving average.

3 aug. 2026, 23:06 UTC

Viking Therapeutics shares are higher in after-market trading, reflecting positive sentiment from stronger-than-expected manufacturing PMI data indicating sector growth.

31 iul. 2026, 23:51 UTC

Viking Therapeutics Inc is higher in after-market trading, recovering from earlier session lows after four consecutive declines. The stock remains below its 20-day moving average.

30 iul. 2026, 23:56 UTC

News

Viking Therapeutics Inc. shows a modest gain in after-market hours amid a wave of biopharmaceutical mergers, including Vertex's $10 billion acquisition of Crinetics.

29 iul. 2026, 23:21 UTC

Social Media
News

Viking Therapeutics reported a Q2 loss of $1.10 per share, better than expected. The company highlighted progress in its obesity treatment pipeline.

28 iul. 2026, 23:11 UTC

News

Viking Therapeutics shares are lower in after-market hours amid ongoing challenges and a significant decline over the past two years. Analysts maintain a bullish outlook.

27 iul. 2026, 23:56 UTC

Viking Therapeutics Inc shares are lower in after-market hours, reflecting a lack of specific news and remaining below the 20-day moving average.

Comparație

Modificare preț

Viking Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

185.71% sus

Prognoză pe 12 luni

Medie 90.083 USD  185.71%

Maxim 114 USD

Minim 65 USD

În baza a 14 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruViking Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

14 ratings

14

Cumpărare

0

Păstrare

0

Vânzare

Sentiment

By Acuity

129 / 339 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
help-icon Live chat